专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP3406634A1 ANTIBODIES COMPRISING CHIMERIC CONSTANT DOMAINS 审中-公开
公开(公告)号：EP3406634A1
公开(公告)日：2018-11-28
申请号：EP18179622.8
申请日：2014-01-31
申请人： Regeneron Pharmaceuticals, Inc.
发明人： DAVIS, Samuel , SMITH, Eric , PATEL, Supriya , RAFIQUE, Ashique
IPC分类号： C07K16/28
CPC分类号： C07K16/2809 , C07K16/2887 , C07K16/2896 , C07K16/46 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/53 , C07K2317/71 , C07K2317/732 , C07K2317/734 , C07K2317/92 , C07K2317/94 , C12N15/85
摘要： Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.

2. 发明授权

EP2968494B1 ACTIVATED CARBON FILTRATION FOR PURIFICATION OF BENZODIAZEPINE ADCS 有权
公开(公告)号：EP2968494B1
公开(公告)日：2018-11-14
申请号：EP14763713.6
申请日：2014-03-12
申请人： Seattle Genetics, Inc.
发明人： MEYER, Damon , SUN, Michael
IPC分类号： A61K31/5517 , A61K47/68 , B01D15/08 , C07D487/04 , C07D519/00 , C07K1/34 , C07K16/00 , C07K16/28
CPC分类号： C07K1/34 , A61K31/5517 , A61K47/6803 , A61K47/6849 , B01D15/08 , C07D487/04 , C07D519/00 , C07K16/00 , C07K16/2803 , C07K2317/51 , C07K2317/53
摘要： Disclosed are methods of purifying mixtures comprising benzoidiazepine antibody-drug conjugates.

3. 发明公开

EP3389714A1 BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY WITH PD-1 AND CTLA-4, AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：EP3389714A1
公开(公告)日：2018-10-24
申请号：EP16876434.8
申请日：2016-12-12
申请人： MacroGenics, Inc.
发明人： JOHNSON, Leslie, S. , CHICHILI, Gurunadh, Reddy , SHAH, Kalpana , LA MOTTE-MOHS, Ross , MOORE, Paul, A. , BONVINI, Ezio , KOENIG, Scott
IPC分类号： A61K39/395 , C07K16/28 , C07K16/30 , C07K16/46
CPC分类号： A61K39/395 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/30 , C07K16/44 , C07K16/46 , C07K16/468 , C07K2317/31 , C07K2317/35 , C07K2317/52 , C07K2317/53 , C07K2317/622 , C07K2317/626 , C07K2317/64 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/01
摘要： The present invention is directed to bispecific molecules (e.g., diabodies, bispecific antibodies, trivalent binding molecules, etc.) that possess at least one epitope-binding site that is immunospecific for an epitope of PD-1 and at least one epitope-binding site that is immunospecific for an epitope of CTLA-4 (i.e., a "PD-1 x CTLA-4 bispecific molecule"). The PD-1 x CTLA-4 bispecific molecules of the present invention are capable of simultaneously binding to PD-1 and to CTLA-4, particularly as such molecules are arrayed on the surfaces of human cells. The invention is directed to pharmaceutical compositions that contain such PD-1 x CTLA-4 bispecific molecules, and to methods involving the use of such bispecific molecules in the treatment of cancer and other diseases and conditions. The present invention also pertains to methods of using such PD-1 x CTLA-4 bispecific molecules to stimulate an immune response.

4. 发明公开

EP3371219A2 IMMUNOMODULATORY ANTIBODIES 审中-公开
公开(公告)号：EP3371219A2
公开(公告)日：2018-09-12
申请号：EP16794556.7
申请日：2016-11-04
申请人： Cancer Research Technology Limited
发明人： AL-SHAMKHANI, Aymen , CHAN, Hak Tak Claude , CRAGG, Mark Steven , FRENCH, Ruth Rosemary , GLENNIE, Martin John , WILLOUGHBY, Jane Elizabeth
IPC分类号： C07K16/28 , A61P35/00 , A61K39/00
CPC分类号： C07K16/2878 , A61K39/0011 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/575 , A61K2039/80 , A61P35/02 , C07K16/2818 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/565 , C07K2317/567 , C07K2317/75
摘要： The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.

5. 发明授权

EP2536764B1 ANTI-CD28 HUMANIZED ANTIBODIES 有权
公开(公告)号：EP2536764B1
公开(公告)日：2018-07-04
申请号：EP11707918.6
申请日：2011-02-16
申请人： OSE Immunotherapeutics , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
发明人： MARY, Caroline , POIRIER, Nicolas , VANHOVE, Bernard
IPC分类号： C07K16/28
CPC分类号： C07K16/2818 , A61K39/3955 , A61K47/60 , A61K2039/505 , C07K16/2896 , C07K19/00 , C07K2317/24 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/55 , C07K2317/56 , C07K2317/64 , C07K2317/76
摘要： The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through the CD28 receptor.

6. 发明公开

EP3325512A2 MULTIVALENT AND MULTISPECIFIC GITR-BINDING FUSION PROTEINS 审中-公开
公开(公告)号：EP3325512A2
公开(公告)日：2018-05-30
申请号：EP16828658.1
申请日：2016-07-22
申请人： Inhibrx LP
发明人： TIMMER, John C. , JONES, Kyle S. , RAZAI, Amir S. , HUSSAIN, Abrahim , WILLIS, Katelyn M. , DEVERAUX, Quinn , ECKELMAN, Brendan P.
IPC分类号： C07K16/28 , C07K14/525 , A61K39/395
CPC分类号： C07K16/2878 , A61K2039/505 , C07K2317/21 , C07K2317/22 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/35 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/569 , C07K2317/64 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： This disclosure generally provides molecules that specifically engage glucocorticoid-induced TNFR-related protein (GITR), a member of the TNF receptor superfamily (TNFRSF). More specifically, the disclosure relates to multivalent and/or multispecific molecules that bind at least GITR.

7. 发明公开

EP3313875A1 METHODS AND COMPOSITIONS FOR TREATMENT OF SYMPTOMS ASSOCIATED WITH INTRACRANIAL HEMORRHAGE 审中-公开
标题翻译：用于治疗与颅内出血相关的症状的方法和组合物
公开(公告)号：EP3313875A1
公开(公告)日：2018-05-02
申请号：EP16815424.3
申请日：2016-06-24
申请人： Board of Regents of the University of Texas System
发明人： KRUZEL, Marian L. , ARONOWSKI, Jaroslaw
IPC分类号： C07K14/79 , C12N15/81 , C12N15/85 , A61K9/19 , A61K38/40
CPC分类号： C07K14/79 , A61K38/00 , A61P9/00 , C07K16/00 , C07K2317/21 , C07K2317/41 , C07K2317/53 , C07K2319/30
摘要： Methods and compositions are provided for the treatment of a patient with intracranial hemorrhage (ICH). Methods include the use of the products of recombinant constructs such as those that contain lactoferrin, as well as fusion protein constructs of lactoferrin and Fc domain for IgG.

8. 发明公开

EP3305798A1 USE OF CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS TO TREAT CANCER 审中-公开
公开(公告)号：EP3305798A1
公开(公告)日：2018-04-11
申请号：EP17191702.4
申请日：2011-12-09
申请人： The Trustees of The University of Pennsylvania
发明人： JUNE, Carl H. , LEVINE, Bruce L. , PORTER, David L. , KALOS, Michael D. , MILONE, Michael C.
IPC分类号： C07H21/04 , A61K39/00
CPC分类号： C12N5/0636 , A61K35/17 , A61K38/177 , A61K38/1774 , A61K39/0011 , A61K39/39558 , A61K45/06 , A61K48/005 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/5256 , A61K2039/585 , C07K14/075 , C07K14/525 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K14/70596 , C07K16/2803 , C07K16/2896 , C07K16/30 , C07K16/3061 , C07K2317/53 , C07K2317/622 , C07K2317/76 , C07K2317/80 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/30 , C07K2319/33 , C07K2319/74 , C12N7/00 , C12N15/85 , C12N15/861 , C12N2501/51 , C12N2501/515 , C12N2510/00 , C12N2740/15034 , C12N2740/15043 , C12N2740/15071 , A61K2300/00
摘要： The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.

9. 发明公开

EP3142691A4 METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE AND INFLAMMATORY CONDITIONS 审中-公开
公开(公告)号：EP3142691A4
公开(公告)日：2018-04-11
申请号：EP15792154
申请日：2015-05-15
申请人： BAYLOR RES INSTITUTE
发明人： OH SANGKON , ZURAWSKI SANDRA , JOO HYEMEE , ZURAWSKI GERARD
IPC分类号： A61K39/00 , A01N63/00 , A61K38/20 , A61K39/395 , A61P19/02 , A61P29/00 , C07K19/00
CPC分类号： A61K38/2066 , A61K39/0008 , A61K2039/505 , A61K2039/54 , A61K2039/57 , C07K14/5428 , C07K16/2851 , C07K16/2878 , C07K2317/24 , C07K2317/40 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2319/00
摘要： Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders.

10. 发明公开

EP3293199A1 CHIMERIC ANTIGEN RECEPTORS 审中-公开
标题翻译：嵌合抗原受体
公开(公告)号：EP3293199A1
公开(公告)日：2018-03-14
申请号：EP16187740.2
申请日：2016-09-08
申请人： Heinrich-Heine-Universität Düsseldorf
发明人： Hanenberg, Helmut , Röllecke, Katharina , Wiek, Constanze , Ibach, Tabea , Rössig, Claudia
IPC分类号： C07K14/725 , C07K14/705
CPC分类号： C07K14/70596 , A61P35/02 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70535 , C07K14/70578 , C07K16/2878 , C07K16/2896 , C07K2317/53 , C07K2317/622 , C07K2319/00 , C07K2319/02 , C07K2319/03
摘要： In a first aspect, the present invention relates to chimeric antigen receptors (CAR) composed of at least an extracellular domain, a transmembrane domain and an intracellular domain, the extracellular domain comprises a spacer domain located C-terminally to a ligand-binding-domain also present in the extracellular domain, whereby the spacer domain comprises at least part of the CD34 molecule. Further, the present invention relates to the nucleic acid molecule encoding the same as well as vectors and cells containing the same. The cells include engineered T-cells and NK-cells and derivatives thereof. Further, the present invention relates to a pharmaceutical composition comprising the CAR e.g. in form of a vector, a polynucleotide encoding the CAR or the CAR itself and, in addition, cells, cell lines or host cells accordingly. The CAR according to the present invention is useful in adoptive cell therapy. Finally, a method for enrichment or purification of CAR, in particular, of genetically engineered cells, cell lines or host cells expressing the CAR according to the present invention is provided.
摘要翻译：在第一方面，本发明涉及由至少一个胞外结构域，跨膜结构域和胞内结构域组成的嵌合抗原受体（CAR），所述胞外域包含位于C末端至配体结合域也存在于细胞外结构域中，其中间隔结构域包含至少部分CD34分子。此外，本发明涉及编码其的核酸分子以及包含其的载体和细胞。细胞包括工程化T细胞和NK细胞及其衍生物。此外，本发明涉及包含CAR的药物组合物，例如以载体的形式，编码CAR或CAR本身的多核苷酸，以及相应的细胞，细胞系或宿主细胞。根据本发明的CAR可用于过继性细胞疗法。最后，提供了用于富集或纯化CAR的方法，特别是用于表达根据本发明的CAR的基因工程细胞，细胞系或宿主细胞的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式